🇺🇸 FDA
Pipeline program

JY231 injection

JY-CT-24-005

Phase 2 small_molecule active

Quick answer

JY231 injection for Systemic Lupus Erythematosus (SLE) is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Systemic Lupus Erythematosus (SLE)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials